Health ProductsPublic Communication

Archived - Important safety information for patients taking Lariam (mefloquine) for the prevention of malaria - Hoffmann-La Roche Limited

· Published by Health Canada · Official notice

Details

Alert type: Public Communication
Category: Drugs
Audience: General Public
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Hoffmann-La Roche Limited.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

[Text of letter begins]

Public Advisory
Health Canada Endorsed Important Safety Information on
Lariam® (mefloquine)

January 24, 2005

Subject: Important safety information for patients taking Lariam® (mefloquine) for the prevention of malaria

Hoffmann-La Roche Limited would like to inform patients of updated safety information in the Patient Information leaflet for Lariam® (mefloquine), a medication prescribed to prevent infection with malaria.

The Patient Information leaflet has been revised to help patients recognize symptoms and signs that may indicate rare, but potentially serious, side effects of mefloquine, including mental and heart problems. The Patient Information leaflet contains a new cut-out wallet card with the most important information, and is included in every box of Lariam® tablets. The wallet card is designed for easy removal and should be carried during your travel to areas with malaria and until you have completed your course of therapy with Lariam®.

Revisions to the Patient Information leaflet include:

The most frequently reported side effects with 'Lariam', such as nausea, difficulty sleeping, and bad dreams are usually mild and do not cause people to stop taking the medicine. However, people taking 'Lariam' occasionally experience severe anxiety, feelings that people are against them, hallucinations (seeing or hearing things that are not there for example), depression, unusual behavior, or feeling disoriented. There have been reports that in some patients these side effects continue after 'Lariam' is stopped. Some patients taking 'Lariam' think about killing themselves, and there have been rare reports of suicides. It is not known whether 'Lariam' was responsible for these suicides.

If you use 'Lariam' to prevent malaria and you develop a sudden onset of unexplained anxiety, depression, restlessness or irritability, or confusion (possible signs of more serious mental problems), or you develop other serious side effects, including a persistently abnormal heart beat or palpitations, contact a doctor or health care provider. It may be necessary to stop taking 'Lariam' and use another malaria prevention medicine instead. If you can't get another medicine, leave the malaria area. However, be aware that leaving the malaria area may not protect you from getting malaria. You still need to take a malaria prevention medicine.

Do not take 'Lariam' to prevent malaria if you

  • have or had depression
  • have had recent mental illness or problems, including anxiety disorder, schizophrenia (a severe type of mental illness), or psychosis (losing touch with reality)
  • have or had seizures (epilepsy or convulsions)
  • are allergic to quinine or quinidine (medicines related to 'Lariam')

Hoffmann-La Roche Limited has sent a letter to pharmacists and travel medicine doctors to inform them of this new safety information. This information is available on the website of the Therapeutic Products Directorate of Health Canada, at the following address:
http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/index-eng.php

Pharmacists have been asked to provide patients with a Patient Information leaflet with each prescription or refill dispensed.

If you have questions regarding your Lariam® prescription, you are asked to contact your doctor.

Patients and health care providers may report suspected adverse drug reactions to Hoffmann-La Roche Limited, or to Health Canada through the Canadian Adverse Drug Reaction Monitoring Program (CADRMP) at the following addresses:

Hoffmann-La Roche Limited
Drug Information and Safety Department
2455 Meadowpine Boulevard
Mississauga, Ontario, L5N 6L7
or call toll free at 1-888-762-4388
or fax at 905-542-5610
or email to: Mississauga.canada_medinfo@roche.com

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

For other inquiries: please refer to contact information:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Tel.: (613) 954-6522
Fax: (613) 952-7738

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

[Text of letter ends]

 

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime